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FOREWORD
The Space TransportationSystem Three (STS-3) was the third of the four
planned orbital flight tests (OFT) of the Space Shuttle Program. This mis-
sion, though longer than planned due to weather conditions at the landing
site, was successfullycompletedon March 30, 1982. The mission demonstrated
for the first time the eight-daycapabilitiesof a reusablespace vehicle.
The Commanderof the missionwas Jack R. Lousma, Colonel, U.S. Marine Corps,
and the Pilot was C. GordonFullerton,Colonel,U.S. Air Force.
• The primaryobjectiveof the OFT program is to evaluateand demonstrateunder
progressivelydemand1"hgconditions the safe ascent, on-orbit operation and
return of the Orbiter and crew. In additionto the aerodynamicevaluations,a
scientific payload (OSS-1), several experiments (ElectrophoresisEquipment
VerificationTest, MonodisperseLatex Reactor, and Plant Growth Engineering
Test) and the first Get-AwaySpecial (GAS)were includedin this mission. The
medical operationsteam continuedto test and evaluatemedical supportlogis-
tics and evolve concepts for a standardizedprogramto be utilizedduring the
mature STS operations.
The STS-3 mission presentedthe NASA medical team with a seriesof operational
problems associated with the symptoms of initial vestibular responses to
weightlessnessand alteredwork/rest cycles.Medication,alteredcrew activity
plans, and modified f_uid and food consumptionregimenwere prescribedas sup-
portive health maintenanceprocedures. All phases of the mission required
real-time re-evaluation,identificationof potential impact on pre-existing
medical constraints, and development of appropriate recommendations and
solutions. These activities required significant coordination among the
differentmedicaloperationsand missioncontrol teams.
This report is intended to be a detailed medical evaluation of the STS-3
mission.
Arnauld E. Nicogossian,M.D.
Manager,OperationalMedicine
Life SciencesDivision
NASA Headquarters
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INTRODUCTION
The Space TransportationSystem Three (STS-3)was launchedon March 22, 1982,
at 15:59:59:785G.M.T. from KennedySpace Center,Florida,for a planneddura-
tion of seven days. The mission was originally planned for a landing at
Edwards Air Force Base, California,but due to adverse (wet) lake bed runway
conditions,the primary landing site was moved to White Sands, New Mexico.
Again, adverse weather conditions changed the plan. This time blowingdust
caused the delay of landingby one day. The Orbiter landed satisfactorilyon
; the eighth day at 16:04:46 G.M.T.,March 30, 1982. The crew for this third
orbital flight test was Colonel Jack R. Lousma, Commander and Colonel C.
GordonFulletrton,Pilot.
The major activitiesof the STS-3 flight were the thermal testing and remote
manipulator system (mS) testing which also had thermal aspects to it. The
major thermaltesting consistedof placing the Orbiter in four central atti-
tudes for extendedperiods of time to determine the thermal responses of
specificareas. These attitudeswere tail-to-sunin orbitalrate, nose-to-sun
twice orbital rate, top-to-sun solar internal,and passive thermal control.
Temperaturesin the tail and nose-to-sun attitudes were maintained within
required rangewith heater duty cyclesless than predictedbecause of slower
thermal responses as demonstrated on STS-I and 2. All payload bay door
closure during the various attitudes were successful except during the
tail-to-sun attitude. This situation was cleared after reorienting the
Orbiterto the top-to-sunattitude for approximately15 minutes followedby a
shortperiod of passivethermalcontrol.
Approximately48 hours of RMS testingwere completedduring STS-3. The major
compromiseto the RMS tests was caused by the loss of the wrist TV camera.
This loss prevented the developmentof the induced environmentcontamination
monitor (ICEM), thereforethe plasma dynamics package (PDP) was used in the
IECM's stead. The PDP weighs about 500 pounds less than the IECM, thus
reducing the effectivenessof the dynamicdata.
All spacecraft systems operated satisfactorilythroughoutthe STS-3 mission
with onlyminor problemsthat did not impact the conductof the mission.
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EVALUATIONOF CREW HEALTH ;
; ,_ _-
Craig L. Fischer,M.D. and James M. Vanderploeg,M.D.
PRE-FLIGHTINTERVAL
The F-30, F-IO and F_ pre-flight physical examinationswere conducted on
schedule and were essentiallynormal. The only pre-flightmedical problem
presentedwas an apparent upper respiratoryinfection,•experiencedby one of
; the crewmen.
From a laboratoryperspective,this crewman exhibitedan absolute neutropenia
and relativelymphocytosison F-IO, associatedwith a minimal rise in the ZSR.
By F-2, the absoluteneutropeniawas remitting. These laboratorydata, plus a
negative throat culture for bacterial pathogens, when integrated with the
presenting clinical symptoms of mild nasal congestion, injected throat and
afebrile state strongly suggest a viral etiology,for the upper respiratory
infection. Other pre-flightlaboratorydata of this crewmanwere remarkable
with respect to the Alk-Phos and SGOT (AST) results. These enzymes showed a
minimal and transientrise on F-2, unassociatedwith changesin the SGPT (ALT)
and GGTP values. In addition, no increase in the slow zone LDH isoenzyme
activity(liver related)was noted during this interval. Becauseof the small
magnitude of the Alk-Phosand SGOT enzyme elevationsand their disassociation
with other sensitive hepatobiliary and liver parenchymal enzyme markers,
statisticalvariationsratherthan clinicalliver diseasemust be implicated.
On flightmorning,both the Commanderand Pilot were in excellentphysicaland
mental status.
POST-FLIGHT INTERVAL
Because of weather conditions,the landing was moved to Northrup Strip, New
Mexico. The Crew Physicianenteredthe Orbiterapproximately10 minutes after
wheel stop. Upon enteringthe mid-deck,specificnotice was made of any odors
emanating from the spacecraft. There were none. The atmospherewithin the
Orbiterwas odorless.The Crew Physicianascendedthe ladder from the mid-deck
to the flight deck and found both Commanderand Pilot sitting,with helmets
off, in their respective seats. Both men were smiling and in no obvious
distress. Their comments were spontaneousand appropriate. The Commander
then egressed his seat and at the surgeon'srequest checked all the switch
positionsand associatedconnectorsof the bio-med sensors. No anomaly was
found. He then descended,without difficulty,to the mid-deck. He stated he
felt "heavy and had light-headedness",but upon questioningthe lightheaded-
ness was more an unsteady sensationand was unassociatedwith clinical symp-
tomology. He did not experience vertigo at any time. The Commanderalso
stated he was somewhatwarm and thirsty. He was offered an oral electrolyte
solution and drank approximately700 cc over a period of 2 minutes while
standingon the mid-deck.
By this time the Pilot had descended the ladder from the flight deck to the
mid-deck and the Commandermoved to the white room just outside the Orbiter's
hatch. The Pilot mentionedhe was also thirstyand consumedan estimatedlO0
cc of the oral electrolytesolutionover a periodof one minute. Subsequently,
the Commanderand Pilot walked down the steps from the Orbiterto the desert
floor without assistanceor difficulty. Once inside the crew van, the suits
were doffed and no evidence of excessiveperspirationwas found in any of the
garments. The ride from the Orbiter to the medical examining facilitywas
short and no significantmedical problem was encountered.Once inside the
medical exam facilities,the crewmen were debriefed according to plan. The
physicalexaminations,includingthe stand tests, were unremarkable. Follow-
ing the examinations,the crew consumedmore of the oral electrolytesolution,
with the Commanderdrinkingan overalltotal of 816 mls and the Pilot 203 mls.
These totals includethe amount consumedon the Orbiter.
The post-flightlaboratory data revealed an expected, absolute neutrophilia
demonstratedby both the Commanderand Pilot. This findingreverted to normal
range by the L+3 examinationand may be attributedto an epinephrineresponse.
The Commanderand Pilot both showed minimal elevations in serum creatinine,
unassociatedwith an increasedBUN or uric acid. The Pilot exhibiteda modest
increase in Alk-Phos post-flight,which was unassociatedwith an increase in
the GGTP,therefore suggestingbone origin. This modest post-flightincrease
returned toward normal by L+3. The Pilot also showed a transientand minimal
elevationof the total LDH at L+O which slowly fell towards normal by L+IO.
Review of the Pilot's pre-flight LDH data reveals near equality and actual
reversalof the LDH 1:2 ratio during the pre-flightinterval. The post-flight
data showed no major departure from the previouslyestablishedpattern. No
significantalterationsin the CPK totals or isoenzymespatternswere recog-
nized in any time interval.
In summary, no significant health problem was detected in the post-flight
interval.
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INFLIGHTMEDICALOBSERVATIONS
MichaelW. Bungo,M.D.
The approachto inflightmedicalassessmentand care for STS-3 was the same as
that described for earlier Shuttle flights in documentssimilar to this one.
In short,a privatemedicalconferencewas held daily betweenthe crew and the
Mission OperationsControl Room (MOCR)Surgeon.
; Launch occurred at 16:00 GMT on March 22, 1982. The first private medical
conference (PMC) was held 7 hours and 20 minutes into flight. At that time,
the pilot (PLT) reported he was "feeling great". The commander (CDR), how-
ever, reported that he began to have space motion sickness symptoms at the
time of OMS-1 (about 19 minutes into the flight). He took a Scope/Dexcapsule
at_that time and a second dose 4 1/2 hours into the flight. Within 1/2 hour
after this second dose and having been moving around for suit doffing, he
experiencednauseaand vomitedonce. He was asked to continuemotion sickness
prophylaxis(Scope/Dex)one capsule approximatelyevery 4 hours while awake
and continuing throughthe second day. The CDR reported that even though his
food intake was reduced, he was especiallyconsciousof continuingto consume
fluids. Waste water tank levels seemed to be consistentwith reasonableout-
puts. When the PMC was held on the second day, it was obviousthat both crew-
men were not feelingwell. First, they had been awakenedmultipletimes during
the night because of static in their headsets as they passed over certain
regions of Asia. Secondly,the CDR's appetitewas depressedalthoughhe had
not experiencedfurtherepisodesof vomiting. Thirdly,the PLT had developed
symptomsof loss of appetiteand had additionallydevelopedsome low back pain
which, on further questioning,appeared to be musculoskeletalin origin and
similarto problemsencounteredon prior space flights.
The MissionControl Center flight team subsequentlyrearrangedthe crew acti-
vities plan (CAP)to switch tasks on mission day 3 for tasks scheduled for
mission day 4. This providedan easier day for the crew earlier in the mis-
sion so that they might have time to recover from the space motion sickness
syndrome. In addition,they were allowedan extra hour of sleep time. Unfor-
tunately, the cabin was reported to be "chilly" during the night which was
probably due to the scheduled tests being performed to characterize the
Orbiter'stemperatureresponseto differentattitudes.
The third PMC (24 March 1982, 20:20 GMT) found both crewmen still having symp-
toms of anorexiaand lassitude,but both were improvingtheir functionalcapa-
cities.
Minor system problemscontinuedto plague the crew such as cool cabin tempera-
tures, drink bottles which had the filling stems broken and jamming of the
waste collection system slinger by an emesis bag. On day 6 of the flight
(March 27), both crewmen used the passive treadmill supplied for their
exercise. Only brief tryout periodswere utilized,but they reported promise
in its functionalcapabilities.
During day 7 of flight, the crew was obviouslyin excellent spiritswith no
medical residual from their previoussymptoms.
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Entry was scheduledfor the morning of March 29, 1982. As part of the prepa-
ration for landing,both crewmembersconsumed 1000 cc of an electrolytesolu-
tion as a means of increasingtheir blood volume. On the last revolution of
the Earth, however, it was obvious that sand storm conditionswould preventa
landing at Northrup Strip, New Mexico, therefore the entry procedure was
delayed for 24 hours.
A PMC held the eveningof this wave-off day revealed the crew to be asymptoma-
tic and in good spirits. The followingmorning, they purposely drank addi-
tional fluids but no longer had any specific "entry beverage"as they had on
the precedingday.
The anti-g suits were prophylacticallyinflatedby both the PLT and the CDR at
entry interface minus 6 minutes. No discomfort from the suits or from g
forces was reported by the crewmembers. Electrocardiographicdata were
obtained on the CDR but not the PLT. The cause of this malfunctionis not
clear as satisfactorydata had been obtained from both crewmen during the
launch phase and during the abortedlandingphase one day earlier.
Touchdownoccurred at 16:05 GMT on March 30, 1982. The crew egressed the
Orbiter39 minutes later.
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SHUTTLE•ORBITALMEDICALSYSTEM
James M. Vanderploeg,M.D.
The ShuttleOrbiterMedicalSystem (SOMS-A)is an outgrowthof onboardmedical
kits which have been in use throughoutthe history of manned space flight.
The STS-1Medical Reportcontainsa brief summaryof previousmedicalkits and
training.
; SOMS'Awas designedfor use during the OrbitalFlight Tests to provide treat-
ment capability for life-threateningemergenciesand to permit diagnosisand
treatmentof many less severe illnessesand injuries. The inventoryof the
SOMS-A is intendedto sustainthe medical needs of a two-mancrew for up to 14
days.
The total system is composedof the Medicine and Bandage Kit (MBK), the Emer-
gency Medical Kit (EMK) and the Medical Checklistof the Flight Data File. A
descriptionof the organizBtionof the two medical kits can be found in the
STS-1 and STS-2 Medical Reports. The basic organizationof the kits was
unchangedfor STS-3. The MedicalChecklistwas modified by making the alpha-
betical and usage lists of the kits' contents a Flight Supplement. This
allowschanges in medicationsfor the particularrequirementsof a crew to be
made without having to change and reprint the Medical Checklist sections on
Emergencies,LaboratoryMedicine and Illustrations. '
The evaluationof an individualastronaut'ssensitivityto any of the drugs
present in the medical kit has been a part of premissionpreparationthrough-
out the historyof the space program. Knowledgeof _ny •allergicreactionor
undesirable side effects to the medical kits contents is imperative for
effectivehealth care by the Mission OperationsControl•Room (MOCR) Surgeons
and Crew Physicians.
As was done in the past, a drug sensitivityevaluationwas conductedprior to
the STS-3 flight. This evaluationwas carriedout in two segments. First,
the health record of each crewmemberwas reviewed and every medication which
he had receivedeither for a clinical indicationor for previousdrug sensiti-
vity testingwas recorded. Any rep.ortedreactionsor side effectswere also
recorded.
The secondsegmentof this evaluationinvolvedtestingof each crewmemberwith
thosemedicationswhich were felt to have a high likelihoodfor use in flight
This testingwas scheduledin such a way that no flying was undertakenfor 24
hours followingthe ingestionof any medication. Most of the tests were done
in conjunctionwith flight simulationexercises. Sedativeswere taken at home
in the eveningto evaluate sleep inductionas well as alertnessthe following
day. Prior to being issued any medication the crewmemberwas briefed on pos-
sible side-effectsand allergicmanifestationsand on the procedureto follow
to obtain emergencymedical attention,if needed. _
The information gained from the drug sensitivity evaluation was checked
against the contentsof the SOMS-A. Thus, the physiciansmade certainthat no
medicationswere carriedon board to which a crewmanwas unusuallysensitive.
EMERGENCYMEDICALSERVICESSYSTEM(EMSS)
NormanBelasco
Planning
Planning for the STS-3 EmergencyMedical Services (EMSS) utilized an updated
STS-I format. The most significantchange implementedfor STS-3 was transfer-
ring the responsibilityof EMSS Coordinator at the Mission Control Center
(MCC) from the Chief of the Medical Sciences Divisionto each Mission Opera-
tions ControlRoom (MOCR)Surgeon on shift. Assignmentsfor EMSS Flight Sur-
geons at the participatingsites were:
*KSC Crew Physician Dr. Fischer
Deputy Crew Physician Dr. Vanderploeg
EMSS Coordinator . Dr. Buchanan
Helo FlightSurgeons Dr. Bagian
Dr. Vanderploeg
Departmentof Defense (DOD) Flight
SurgeonBackup
*DFRF/EAFB Crew Physician Dr. Fischer
Deputy Crew Physician Dr. Vanderploeg
EMSS Coordinator Dr. Hadley (Dr.McBride,alt.)
Helo Flight Surgeons Dr. Seddon
Dr. Thagard •
DOD Flight SurgeonBackup
*NS AlternateCrew Physician Dr. LaPinta
EMSS Coordinator Dr. Bergman
Helo Flight Surgeons Dr. A. Fisher
Dr. W. Fisher
DOD FlightSurgeonBackup
*CLS Search and Rescue (SAR) Rescue forces,local availability
DOD Site ResponsibleMedicalOfficer- EMSS Coordinator
*KennedySpace Center,Dryden Flight ResearchFacility/EdwardsAir Force Base,
Northrup Strip,ContingencyLandingSite.
Since the STS-3 landing site changed from DFRF to NS and considerationfor
change again to KSC was being made in real time, the remainderof the related
planningaspectsare discussedunder Results.
Training
In preparationfor STS-3, EMSS oriented trainingwas conductedby participa-
ting in joint NASA/DOD rescue exercisesat KSC, DFRF, and NS. Simulations
were held with each of the contingencylandingsites (CLS's)locatedat Rota,
Spain; HickhamAFB, Hawaii;and Kadena AFB, Okinawa.
6
At DFRF and NS the rescue exercises included aided egress modes at landing,
for both on-runway and off-runway contigencies(on land). At KSC the exer-
cises included aided egress modes for a landing mishap on the runway and a
landingmishap off the runway (in water). For the rescue exercises,detailed
scenarioswere appropriatelycoordinated,and live subjects (as planned) were
used at KSC for the on-runwaylandingmishap and for the water rescue. Con-
tact with CLS needed improvement at Rota and Kadena AFB. Hickham AFB
respondedflawlessly,as required,with all assignmentscarriedout in accord
with the initial contact procedures and overall knowledge of communications
protocol,althoughDDMS took action to improveboth site'sresponsiveness.
Resultsand Discussion ......
Because of a weather problem and unacceptablelakebed landing conditions at
EAFB/DFRF,the decisionwas made prior to launch to land at NS, End of Mission
(EOM).
For EMSS landing coverage,it was decided to deploy the Crew and Deputy Crew
Physicians(afterlaunch and Returnto LaunchSite, RTLS) from KSC directlyto
NS, positioningDr. Fischer (Crew Physician) in the convoy crew vehicle and
Dr. Vanderploeg (Deputy Crew Physician) at the strip dispensary where:the
postflightcrew physicals are conducted. Helo Flight Surgeons who were in
place at DFRF and NS were to remain, as were the Helo Flight Surgeonand DOD
Backup Flight Surgeon at KSC (who replaced the Deputy Crew Physician after
launch). The EMSS Coordinatorfor NS remained on stationthroughoutat buil-
ding 300, WSMR, where the STS-3 EMSS communicationconsole is located. Once
the EOM Medical Operationscomplementwas in place at NS, a decisionwas made
for the alternate Crew Physician to remain at NS in position at the strip
OperationsCommunicationCenter (OCC). The above deploymentchangeswent very
smoothly. Additionally,the Holloman AFB Hospital and the William Beaumont_
Army Medical Center Definitive Medical Care Facility (DMCF) were alerted to
the NS landingplan. .
Shortlybefore the planned EOM time at NS, high winds forced a mission exten-
sion and possiblelandingchanges that includedconsiderationsof a landingat
KSC on the hard surfacedShuttleLandingFacility (SLF).
AcCordingly,arrangementswere made to supportthe EMSS adequatelyshould the
landing be at KSC. On the 9th day of the mission, EOM occurred at NS as a
nominallandingwith unaidedegress and withoutneed for EMSS implementation.
The abilityto redeployEMSS teams went smoothlyand without significantinci-
dent attesting to a satisfactoryaccommodationof required flexibility. All
Participantswere cooperativeand respondedin a professionalmanner.
It is apparentthat EMSS at landingsites is heavilydependentupon the inclu-
sion of FOD and DOD personnel. At present,within the MedicalSciences Divi-
sion alone, there is not a sufficientnumber of qualifiedFlight Surgeonsto
staff all the EMSS positionsin supportof landingswhen EAFB, NS, and KSC are
primary,backup,and secondarysites.
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VALIDATIONCF PREDICTIVETESTSAND COUNTERMEASURES
FOR SPACEMOTIONSICKNESS
Jerry L. Homick, Ph.D,
Backgroundand Purpose
Experiencefrom previousmanned space flight indicatesthat the space sickness
syndrome represents a potential threat to the operational efficacy and
physical well being of future space flight crewmembers. Because of its
complexity and uniqueness this biomedical problem cannot be resolved solely
with ground based research. To obtain final and valid solutionsit is essen-
tial that data be collected systematicallyon individuals who fly Space
Shuttlemissions.
A Flight SupplementaryObjective (FSO) was developed to initiate this data
collectionprocesswith the STS-1 and STS-2 missions. A nearly identicalFSO
($343)was implementedfor the STS-3 mission.
A primarypurpose of this FSO was to conduct inflightobservations,supported
by a series of preflightand postflightdata collectionprocedures,on STS-3
crewmembersin an effort to validate ground based tests which may be predic-
tive of susceptibilityto the space motion sickness syndrome. An additional
objectivewas to implementcrew testing procedureswhich would enable acqui-
sition of data to be used in validatingmotion sicknesscountermeasures.
Test Description
Preflight
Part of the requiredcrew preflightactivitywas based on guidelinesset forth
in NASA'smedical operationspolicy for the prophylaxisand treatmentof space
motion sicknesswith anti-motionsickness drugs. This policy states in part
that astronautswith a positive history of space sickness or with no space
flight experiencewill be premedicatedwith a properly selected anti-motion
sickness drug. The policy further states that astronautswhohave flown in
space with no symptomsof space sicknessare not requiredto be premedicated.
Any individual who experiences space motion sickness will be administered
appropriateinflight treatment with anti-motionsickness drugs. The policy
requires preflight side effects screening and efficacy testing with one or
more anti-motionsicknessmedications.
During the preflightperiod (at approximatelyF-180 days) each crewmembercom-
pleted a questionnairedesignedto elicit pertinentinformationregardingpast
experienceswith various types of motion environmentsand responsesto those
environments.
Between approximatelyF-180 and F-160 days, both crewmembersconferred with
the STS-3 Flight Surgeon to select a preferred anti-motionsicknessmedica-
tion. The selected medication was administeredto them to determine the
possibility of any adverse reactions. The drug screening was done under
operationalconditions(e.g., Shuttlesimulatortraining)and verbalreporting
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by the crewmemberswas relied upon. Each crewmember'spast experienceswith
anti-motion sickness medications were also Considered in selecting the
preferredmedication for STS-3,
At approximatelyF-175 days, the crewmemberswere each tested one time for
susceptibilityto experimentallyinduced motion sickness in the JSC Neuro-
physiologyLaboratory. The standard Coriolis Sickness SusceptibilityIndex
(CSSI) test was used. This procedurerequires the performanceof head move-
ments while rotating at a constantvelocity in a servo-controlledchair. The
test was terminated when the crewmembers reached the Malaise Ill level (8
' symptompoints)of motion sicknessor performed150 head movements,whichever
occurred first. Duringthis test, session_thecrewmemberswere instructedon
. the self-recognitionand reporting of motion sickness symptoms. They were
also instructedon the use of the microcassetterecorderand inflightsymptom
checklist.
Two weeks after the laseline CSSI test, the CSSI test was repeated on each
crewmember to determinethe efficacy of orally administeredscopolamineplus
dexedrine (Scope/Dex)in preventingmotion sickness. A second anti-motion
sickness drug efficacy test involvingtransdermallyadministeredscopolamine
was conductedwith the PLT two months after the Scope/Dexefficacytest. The
scopolamineskin patch was administered16 hours prior to testing.
Inflight
A microcassettetape recorder and symptom checklist was stowed onboard the
Shuttle Orbiter. The two flight crewmenwere requiredto use the recorderand
checklist during a designated time (pre-sleep period) each mission day to
debriefon any motion sicknesssymptomsor vestibularsensationsthat had been
experienced.
Postflight
Questionspertainingto motion sicknessand vestibular sensationswere asked
of each crewman on L+O and during the postflightmedical debriefing. Two
additionalmotion sicknesssusceptibilitytests were also requiredpostflight.
These are the off-verticalrotation test and the sudden-stoptest, both of
which were to be performedonce .oneach crewman during the L+IO to L+90 time
period.
Test Results
The preflightmotion experiencequestionnaireindicatedthat both crewmembers
had a minimal historyof terrestrialmotion sicknesssusceptibility. Adequate
preflight baseline CSSI test data were obtained on both crewmembers. The
results indicatedthat both crewmemberswere moderatelyresistantto the ves-
tibular stress induced by the CSSI test. Oral Scope/Dex was judged to be
effective for both crewmembers,particularlyfor the CDR. The scopolamine
patch was relativelyineffectivefor the PLT and producedmore noticeableside
effects than Scope/Dex.
In accordance with the medical operations policy for the prophylaxis and
treatmentof spacemotion sickness,both crewmentook one oral Scope/Deximme-
diatelyafter the OMS-1 maneuver.
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Shortly after the OMS-2 maneuver,the CDR egressed from his seat and began to
move about on the flight deck and mid-deck of the vehicle. The CDR reported
that the movement induceda generalmalaise includingmild nausea. At about 4
1/2 hours into the mission, the CDR took a second Scope/Dex. Approximately
one-half hour later, increasedmovement associatedwith removing his flight
suit, caused the CDR to experiencemore severe nauseawhich quicklyculminated
in a•single episode of vomiting. The CDR continued to experience a general
malaise and decreasedappetite the remainderof mission day 1 and restricted
his head and body movements. The feelingof malaise persistedthroughmission
day 2 and gradually subsidedby the end of day 3. By mission day 4 the CDR
reported feeling normal and had a good appetite. Additional Scope/Dex was
used by the CDR onmission days 2 and 3. "
It is significantto note that the STS-3 CDR was also the PLTof the 59-day
Skylab 3 mission. On that flight he experiencedrelativelysevere symptomsof
space motion sicknesswhich persistedthrough the fifth day of flight. The
CDR reported that his symptomson STS-3 were not as severeor as long lasting
as his symptomson Skylab 3.
Followingorbitalinsertionthe STS-3 PLT remained in his seat for a slightly
longer period of time than did theCDR. When the PLT first began to move
about in the vehicle he experienceddizzinessand a vague uncomfortablesense
of disorientation. The PLT reported that the sensationwas aggravatedsome-
what by head movementsand thereforemoved cautiouslyduring most of mission
day 1. On mission day 2 and 3 the PLT's overallfeelingof well being worsened
slightly. He reported having no appetite,a lack of energy and had to force
himself to work. On mission day 4 his appetiteimprovedwith increasedfood
intakehe rapidly improved. The PLT reportedthat vigoroushead movementsdid
not aggravate his lack of well being after mission day 1. In addition to
three Scope/Dexcapsulestaken on mission day 1, the PLT used two Scope/Dexon
mission day 2 and one on mission day 3.
10
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CREW CARDIOVASCULARPROFILE
MichaelW. Bungo,M.D.
As in previous Shuttlemissions,cardiovasculardata were obtained purely in
an operationallyorientedmode. Simply stated,these data consistedof a pre-
and postflight"standtest". This methodologyhas been describedin the STS-1
Medical Report but in short, is a measure of heart rate and blood pressure
, response as a result of change in orthostaticposition. In addition,heart
rate data from ECG monitoringwas obtainedon both crewmenduring:thelaunch
phase of flight, and heart rate data on the commander (CDR) was obtained
during the entry phase of flight. Entry heart rate data on the pilot (PLT)
was not obtained because of mechanicalfailure of the biomedical harness
connector.
Ascent heart rates were similar to those reported for previous Shuttle mis-
sions and do not warrantnumerationin this report. Uniqueto this flightwas
that the crew inflatedtheir anti-g suits approximately6 minutesbefore entry
interface(at least 30 min before touchdown). Becauseof decreasedcalf size
occurring as a result of adaptation to microgravity,the suit may not have
delivered its set compressionpressure. Certainly,the effect of g forces
clearly indent the heart rate profile data: however, no cardiovascularsymp-
toms Were experiencedby either crewman.
Similaritiesbetween the F-12 and L+3 stand were readily apparent suggesting
that readaptationwas likely functionallycompleteby the third day or sooner
postflight. Immediatelypostflight,however,cardiovascular"deconditioning"
was in evidence. In spite of volume loads given to both crewmen, the accel-
erationof heart rate upon standingwas obvious. Althoughthe blood pressure
responsesof each crewman differed, they neverthelessresponded in a manner
similarto the two groups that have been seen in prior flights. One crewman
reacted as a "rigid pipe" system in that the volume deletedstate caused both
his systolic and diastolic pressure to fall as the standing posture was
assumed. The second crewman, on the other hand, narrowedhis pulse pressure
with a similardrop in systolicpressurebut an increasein diastolicpressure
to what might be considered"hypertensive"levels.
Cardiovascularprofiles similarto previous Shuttle flightswere observed in
the crew of STS-3. "Stand test" results evoked differentresponses in each
crewman but were consistentwith prior experience. There were no clinical
symptoms of o_thostatic intolerance. The use of the anti-g suit did not
preventthe influenceof gravityfrom affectingthe heart rate profile. This
latter findingmay be explainedby inappropriatemechanics of the garmentor
perhapsonly a partiallyprotectiveeffectwas observed.
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BIOCHEMISTRYAND ENDOCRINOLOGYRESULTS
CarolynS. Leach,Ph.D.
The studiesconducted in biochemistryand endocrinologywere to provide data
which, when integratedwith informationfrom other medicaldisciplines,permit
an objectiveassessmentof the individualcrewman'shealth. Additionally,the
data collected during the preflight phase of the Shuttle mission provided
baseline informationfor the medical team in detectingand identifyingphysi-
ological changes which may have resulted from exposure to the space flight
environment. The results of these tests not only helped in the clinical
assessmentof the crewman but also provided data to comparewith previously
acquiredresultson men returningfrom 8 days in space.
Methods and Materials
Analyses were performedon venous blood three times before the mission: 30,
12, and 2 days before lift-off(F-30, -12, -2). Postflightblood was drawn as
soon possible (ASAP) after landing (L+O), 3 days later (L+3), and 10 days
later (L+IO). All blood sampleswere obtainedfastingexcept the L+O sample.
During the preflight and postflight periods, the crew consumed the diet of
their choosing but followed the provided Shuttle diet during flight. Fluids
were available when desired.
Analyses of the blood (plasma or serum) samples included: glucose (Glu),
cholesterol (Chol),glutamic oxaloacetictransaminase(ALT),glutamic pyruvic
transaminase (AST), blood urea nitrogen (BUN), inorganic phosphate (P04),
bilirubin total (Bili T), creatinine (Creat), total creatine phosphokin_se
(CPK) and isoenzymes,total lactic dehydrogenase(LDH) and isoenzymes,osmo-
lality (Osmol), sodium (Na), potassium (K), chloride (Cl), triglycerides
(Trigly),gamma-glutamyltranspeptidase(GGTP), adrenocorticotrophichormone
(ACTH), angiotensin I (ANGLO I), aldosterone(ALDO), and cortisol. Twenty-
four hour urine sampleswere collected30 days before flight and on landing
day. The samples were analyzed for volume, osmolality, sodium, potassium,
chloride, calcium, magnesium, phosphate, uric acid, creatinine, cortisol,
aldosterone,antidiuretichormone,epinephrineand norepinephrine.
The data are given for each crewman. The preflight(PM) and standard devia-
tion (SD) are given as the best preflightcontrolvalues. Each postflight
value obtained is given. The methods and establishednormal range for each
parameter studied are given in the STS-1 Medical Report, NASA Technical
Memorandum58240.
Resultsand Discussion
The results show postflight decreases below preflight findings for choles-
terol, osmolality,Na, and K, for both crewmen. Postflightincreasesabove
preflight values were observed in calcium, angiotensin I, aldosterone,
insulin,T4, and ACTH. Alk phos., GGTP and LDH were slightlyincreasedin the
PLT postflightsamples. Severalparametersfor the two crewmendid not change
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consistently. However, _theseare all in areas Which indicate degree of
stress,state of hydration, and the immediatepostflight activity prior to
blood samplesbeing acquired.
The postflighttwenty-fourhour urine resultsshowed decreasesin osmo, Na, K,
Cl, Mg and uric acid. Increases in excretion of cortisol, aldosterone,
antidiuretichormoneand epinephrinewere observedwhen the preflightvalue is
compared to the first postflight value. Norepinephrine and inorganic
phosphateresultsdifferedfor the two crewmen.
The test resultsof STS-3 crewmenwere similar to the-findingson recoveryof
previous space flight crews. Table I shows the percent differences of the
STS-3 crew's postflight findings compared to preflight values; the percent
differenceof the post- to preflightcomparisonfor the STS-1 and STS-2 crews;
the postflightfindingson the Apollo crewmenwho spent an averageof 12 days
in space comparedto their preflightvalues;and the blood values for infli_ht
days 3, 4 on the Skylab crewmen. This comparisonleads one to the concluslon
that the most dramaticchanges occur and were measured within the first days
of exposureto space flight. Furthermore,these findingson the Shuttlecrew-
men support the •hypothesisthat the changes in fluid and electrolytemetabo-
lism probably occur within hours of reaching orbit as have been shown in
ground simulation.
. • . . .
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TABLE I
Apollo Immediate SL Inflight STS-1 Immediate STS-2 Immediate STS-3 Immediate
Postflight Day 3,4 Postflight Postflight Postflight
% from Preflight % from Preflight % from Preflight % from Preflight % from Preflight
Parameter Mean Mean Mean Mean Mean
Osmolality -0.7 -0.6 -0.5 5.0 -1.2
Na -0.4 -1.5 -1.0 -1.0 -2.1
K -7.3 3.6 -6.8 -12.8 • -6.2
Cl -0.6 -0.9 -1.0 3.0 0.5
Ca 1.0 6.5 1.8 6.8 6.6
Mg -5.0 -2.5 :4.8 8.4
PO4 0 11.7 12.5 1.9 17.2
BUN 11.9 25,5 1.7 6.3
Creatinine 8.3 4.3 9.3 10.7 11.6
Glucose 9.8 4.2 1.0 2.6 64.2
Triglycerides -24.3 -31.0 -32.0 9.3
Cholesterol -6.0 -3.0 17.0 -7.5
•- Uric Acid -14.8 •-22.0 12.0 -10.4
Total Bilirubin 12.5 -12.5 113.0 -14.6
AlkalinePhosphatase 2.8 1.3 ; 18.0 13.7
GGTP 19.1 33.8 16.0
Lactic Acid Dehydrogenase -10.1 5.3 , 27.0 13.8
SGOT (AST) -4.2 -14.3 -55.0 -2.0
SGPT (ALT) 0 5.9 •-28.0
CreatinePhosphokinase -11.3 -6.0 61.0 -6,8
AngiotensinI 488.0 135.3_ 80.0 275.0 252.7
Cortisol -27.0 -7.5 -11.0 92.0 -17.5
Insulin 32.0 -9.1 81.0 362.0 355.1
T3 -1.0 3.3 -5.0 9.5
T4 12.0 11.5 31.0 17.4
TSH -2.3 59.9 10.9
HGH 304.0 52.1 5.5 30.0 -25.0
ACTH -24.0 -58.3 54.8 -24.0 98.9
Aldosterone -4.7 54.8 59.9 80.1
HEMATOLOGICALAND IMMUNOLOGICALANALYSES
Gerald R. Taylor,Ph.D.
Hematologicaland immunologicalanalyses wereconducted on the primary and
backup cre_membersof STS-3 so that body-functionvalues necessary for_the
objective assessment of the health status of the crew before launch and
immediatelyafter flight could be evaluatedby the medical staff.
Materialsand Methods
Blood sampleswere collectedby venipuncturefrom the two prime crewmembers
30, 12, and 2 days before flight (F-30, F-12, F-2 respectively);within 2
hours after landing (L40);and 3 and 10 days after landing (L+3, L+IO). The
backup crew was sampled35, 11, and 3 days before flight (F-35,F-11, F-3).
Cellular immunology analyses were conducted on blood collected with sodium
heparin whereas Ethylene Diamine Tetra-aceticAcid (EDTA) was the anticoagu-
lant of choice for the cellularhematologymeasurements. Humoral evaluations
were conducted on serum from standard clot tubes. In all cases, Vacutainer
(TM) tubes were used for blood collection.
Results and Discussion
The resultsof analysesconductedon the cellularblood componentsdemonstrate
that for the one month period preceding the flight, there were no unusual
variationsin the cellularblood componentsof the four crewmembers. However,
there were important alterationsin both of the primary crewmembers after
flight.
Evaluationof these data demonstratethat for the one month period preceding
the flightthere were no unusualvariationsfrom the norm with any of the four
crewmembers.
The immediatepostflight values for both crewmembersindicate a loss (about
8%) in erythrocytenumber when comparedwith the preflightmean. This should
translate into a 4% change in the hematocrit which was the case with the
Pilot. The postflightdecrease in the hematocritof the Commanderwas not as
marked, owing to the greater increase in the size of the erythrocytes,as
illustratedby a greatermean corpuscularvolume (MCV). These data show that
there was a postflight:
1) Absolute loss of erythrocytenumber
2) Increasein erythrocytevolume
3) Stable hydration/dehydrationstate
4) Increasein corpuscularhemoglobincontent (MCHC)
As has been reportedfor previous Shuttleflightsthere was a marked increase
(113-116%)in the postflightwhite cell count. As there was no evidenceof a
fluid shift, this can be considered an absolute change. As with previous
15
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flights,this increase in peripheralblood neutrophilsis regarded as part of
the "stressresponse". However,unlike other flightsthere was essentiallyno
postflightchange in the number of peripherallycirculatinglymphocytes.
Lymphocytesextracted from crew blood sampleswere reacted with the mitogen
Phytohemagglutinin(PHA) to assess the competence of the in vitro immune
response. After a suitable incubation period the blastogen_ response was
measured by determiningthe incorporationof radioactivethymidineinto newly
formed DNA. For the Commanderthere was a significant(p<O.01) postflight
decreasein the ability of lymphocytesto respondto mitogenTcassault. This
depression had essentially returned to normal by the third day after the
flight. The responsivenessof the Pilot'scirculating lymphocytes was
depressed two days before the flight and remained atthe same low level I
through the last sampling period which was 10 days after completion of the
mission.
°,
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MEDICALMICROBIOLOGYOF CREWMEMBERSAND SPACECRAFT
DuaneL. Pierson,Ph.D.
Crew Sample Collection
Samples were collected from each prime crewman for microbial evaulationat
F-30, F-IO, F-2, L+O, and L+3. The backup crew was sampledat the same desig-
nated preflighttimes, but no postflightsampleswere collected. The samples
consistedof swab samples from the ears, nose, and throat; a fecal specimen
(or rectal swab);and a midstreamfirst-voidurine specimen.
SpacecraftSample Collection .....
Microbiologymonitoringof the spacecraftwas comprisedof collectingand ana-
lyzing samplesfrom the Orbiter'sinteriorsurfaces,flighthardware,air, and
potablewater supply.
Resultsand Discussion
Crew Microbiology
All crewmembers exhibited absent or normal microbial flora in ears, nose,
throat,urine, and feces cultures.
SpacecraftMicrobiology
Twenty_ne surface sites on the mid and flight decks were sampled at F-30,
F-2, and L+O. The prelaunchlevels of bacterialcontaminationwere somewhat
higher than observed during STS-1 and 2. Nearly all sites exhibited higher
numbersof bacteriaat L+O. The number of fungi per site was low at prelaunch
sampling periods. However, at L_O almost all sites exhibited much higher
levels of fungi. The F-30 sample period prior to STS-4 will be very important
in assessingthe cleanupproceduresemployedbetweenflights.
No bacterialpathogenswere isolated. However, twelve different species of
the pathogenicfungalgenus, Aspergillus,were isolated. Interestingly,three
of these species,A. sydowi,A. phoenicis,and A. amstelodami,were isolated
. from the crewmen post _ing. None of these species were cultured from
either crewmanprior to launch.
ShuttleFoods
Random samplesof all foodstuffsstored onboard the Orbiter were analyzed to
assure that acceptablemicrobial levels were not exceeded. The analytical
proceduresand microbiologicalstandardshave been establishedfor both non-
stabilized and thermostabilizedfoods. No food samples submitted to the
laboratoryfor the STS_ mission failedthe acceptancestandards.
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Crew Virology ,
The crewmen (prime and backup) were evaluated to determine their immune status
to specific viral agents. Serum samples were screened for hepatitis B surface
antigen and antibody to the hepatitis A antigen at F-30, F-tO, F-2, L+O (prime
crew), and L+3 (prime crew). No evidence of infection (prior or current) was
found in any of the crewmen. It was determined by the Health Stabilization
Officer that the crewmen had sufficient immunity (previously determined) to
rubella, rubeolla, and mumpsviruses to make a current evaluation unnecessary.
Throat and rectal swabs were taken of the crewmen at F-IO, F-2, and L+3.
These specimens were evaluated for the viral agents,
Prior to the mission the prime commander was exposed by a family member to
what was suspected to be Epstein-Barr (mononucleosis) virus. Serum samples
were immediately examined to determine the immune status of all crewmen to EB
virus. All crewman exhibited titers indicative of prior infection and were
probably sufficiently immune.
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• FOOD AND NUTRITION _
RichardL. Sauer and RitaM. Rapp
The menus for STS-3 were designedto maintaingood nutritionby providing3000
kilpcaloriesand at least the recommendedlevels of nutrientslisted in Table
1. Food intake records shown in Table 2 for the STS-3 Commander (CDR) from
his Skylab 2 mission indicate that 3000 kilocaloriesper day were not a
sufficientdaily energy allowancefor this individual. In order to assure an
adequatefood supply for the STS-3 CDR, additionalfood itemsWere includedto
increasethe menu allowanceto approximately4000 kilocaloriesper day. The
• supplemental foods listed in Table3 were overwrapped,labeled by day of
intendeduse, and stowedin locker trays with the pantry food.
Eight entry beverageswere provided for fluid loading as a countermeasureto
cardiovasculardeconditioning. Each crewman was requested_to consume four
beveragesprior to entry into the Earth'satmosphere. Originalplans were to
use Wyler'sbeef bouilloncubes (2.9 g/8 oz water) packagedin flightbeverage
containers;however, Gatorade (16 g/8 oz water) was finally selectedfor this
purpose.
Preflightfood servicewas provided for the STS-3 prime, backup, and support
crews during countdowndemonstrationtests (CDDT)and the Health Stabilization
period. Meals were preparedand served at both the JSC food facilityand the
KSC crew quarters.
Postflight food service was provided• for the prime crew immediately after
touchdownat NorthrupStrip,New Mexico,and for the return flightto Houston.
There was no requirementto measure inflight nutrient intake; however, this
was estimatedafter the mission. The crew ate breakfastin the crew quarters
at KSC prior to launch. This meal is not included in the nutrient
calculations.
The entry beverageswere consumedon the day of scheduledentry prior to the
time a sand storm at NorthrupStrip caused a landingdelay of approximately24
hours. There were no provisionsfor an additional set of entry beverages.
Therewas sufficientfood in the pantry for the extra day of flight.
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Table 1: MinimumDaily NutritionalLevels
Suppliedby ShuttleOFT Menus
nutrient amount
kilocalories _ 3,000
protein -. " _56 gm ,
vitaminA 5,000 IU
vitaminD .. 400 IU
vitaminE _ = . 15 IU
ascorbicacid 45 mg
folacin 400 _g
niacin 18 mg
riboflavin 1.6 mg
• . thiamin 1.4 mg
vitaminB6 2.0 mg
vitaminB12 3.0 _g
calcium 800 mg
phophorus 800 mg
iodine 130 _g •
iron 18 mg
magnesium 350 mg
zinc 15 mg
potassium 70 mEq
sodium 150 mEq
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Table2: EnergyIntakefor Skylab2 PLT
Mission : No. of " Mean Daily
,Phase Days Kilocaloric -_
Consumption_ •
Preflight 21 4150
Inflight 59 3875._
.Postflight 18 4220 .
Table3: SupplementalFoodfor STS-3CDR
Day11 No additionalfood
Day 5 Peaches(T) ButterCookies(NF)
Beef Patty(R) ShrimpCocktail(R)
TurkeyTetrazzini(R) RicePilaf(R)
k Cashews(NF) - _
, Day 2, 6 Eggs (R) MeatBallsw/BBQ(T)
PotatoPatty(R) PecanCookies(NF)
Day 3, 7 Chickena la King.(T) RicePilaf(R)
Cashews(NF) Strawberries(R).
, _ Fruitcake(NF)
Day 4 Eggs (R) PotatoPatty(R)
Apricots(NF) Turkeya Gravy(T)
BreakfastRoll (NF) :Peasw/ButterSauce R)
Day 8 Apricots(NF)
BreakfastRoll (NF)
o .
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- THE POTABLE"WATER/_: _''
RichardL. Sauer
The Potable Water System performedwithout difficultiesthroughout the third
Shuttlemission.• The problem of air in the water, noticedon STS-2, did not
occur during STS-3.
Resultsand Discussion ...................
. ..
A total of twelve chemical and nine microbiologicalsampleswere taken from
the potable water system for STS-3. The specific parameterstested for are
those listed in Tables 1 and 2. All parametersof medical concern met the
specificationlimits with the exception_ofthose listed••below,Parametersof
nonmedical concern exceeding the specification limits were total solids
(lOmg/1 max), total organic solids/carbon(3.1mg/1 max), and color (> 50
units).
o Nickel - The water initiallyused to service the water system for STS-3
exceeded the O.05mg/l limit for_nickel. The maximum level of nickel
detected preflight(O.15mg/l)does not representa health hazard. Nickel
levels postf]ightwere within specificationlimits.
o DissolvedGas Dissolvedgas was detectedin the GroundSupportEquipment
(GSE) water used to service the vehicle. Subsequent samples were free
from dissolvedgas.
o Taste and Odor -A slight iodinetaste and odor was detected. The levels
were very low and of no medical consequence.The taste and odor were due
to the iodine concentrationwithin the potablewater storage tank. The
crew receives:water from the water dispenser which strips iodine
concentrationsto a maximum of O.4mg/l.•Tasteand odor of iodinewould not
be detectableat this level.
o Total Bacteria Total bacteriaexceeded the specificationlimit of zero
up to a maxmum of 91 colony forming units•per lOOml (CFU/IOOml)and
32.6CFU/100ml in the ambient and chilled water samples, respectively.
While exceeding the limit, these levels arenot considered significant.
The organismswere identifiedas Flavobacterium,Enterobacter,and Pseudo- J
monas, all being common contaminantsof water, but none consideredpatho-
gens under these conditions.
o Yeast and Mold - One ambient water sample exceeded the yeast and mold
specificationlimit of zero. The level detected was 1.3CFU/IOOmI. The
yeast was identified as .Rhodotorulaminuta var. texensis. Rhodotorula
minuta has not been shown to be a pathogen.
The Shuttle PotableWater System provided the STS-3 crew with water that was
acceptablefor both metabolic and hygenic needs. Although not a medicalcon-
cern, postflightiodine levels were somewhathigher than expected. The crew
was not exposed to these levels since the water dispenserstrips iodine to a
maximum of O.4mg/l. The Potable Water System functioned without problems
throughoutSTS-3.
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TABLE1
PREFLIGHTSTS-3 POTABLEWATERANALYSlS (TANKA)
REF. SE-S-OO73C-TABLE6.4.6
. .. 3/19/82 3/19/82L3i22/82
• Date_'JSC#1 JSC #1. /<'/. /
. '_ " Sample--_
' ' Port ,Ambient Chilled
Parameter Units Ref. Limit
Conducti vi ty ismho - - -
' pH pH ' - ' -
Total Solids mg/l 2-Amb/lO Chilled - , , -.
Total Org Solids/Carbon mg/l ....
Taste and Odor - * - -
Turbidity NTU II max ....
True Color Units 15 max - -
_o Cadmium mg/l 0.01 max - -
' Chromium(hexavalent) mg/l 0.05 max - - _"
Copper mg/l l.0 max - -
Iron mg/l 0.3 max - -
• Lead mg/l 0.05 max - - :=
.." Manganese mg/l 0.05 max - -
Mercury mg/l 0.005 max ,- ._ -
'Nickel mg/l 0.05 max - i - -_
.... Selenium mg/l I1r ' 0.01 max ," I -
Silver mg/l . 0.I max -. ! -
Zinc mg/l ' 5.0 max - -
Dissolved Gas @31°C + None N/A N/A
'Iodine , '• m 1 .
Total ColiformBacteria #/lOOml o 0 0
Total Bacteria #/IOOml 0 4.6B, 132.6B
Anaerobes + 0 0 0
Yeast and Mold #TlOOml ' " ' 0 1.3C 0
•None at threshold,no. of 3.
B. Flavobacteriumand Pseudomonas.
C. Rhodotorulaminuta var. texensis.
TABLE 2
POSTFLIGHTSTS-3 POTABLEWATER ANALYSIS (TANKA)
REF. SE-S-OO73C-TABLE6.4.6
4/2/82 4/2/82 4/2/82 i 4/2)8-2.....4/2/82 4/2/82
Date----_Postflt Postflt PostfltI.Postflt Postflt Postflt
Sample---_ I
Port-----_Ambient Chilled Ambient ! Chilled Ambient Chilled
WSTF WSTF JSC I JSC KSC KSC
Parameter Units Ref. Limit .. i
Conductivity Hmho - 4.0 4.6 6.8 ! 8.3 - -
pH pH - 4.7 .4.6 4,7 - i: 4.6 - -
Total Solids mg/l 2-Amb/iO Chilled - - lO l l.O 2.1 <2.0
Total Org Solids/Carbon mg/l - - - •- ! - - -
Taste and Odor - * - - D - I •E None None
Turbidity ' NTU II max - - _ i _ <ll <ll
True Color Units 15 max - - 50 !_ 50 i>15 _>15
Cadmium. mg/l O.Ol max - - <O.Ol <O.Ol <O.Ol 'i <O.Olhromium(hexavalent) 0 05 - 0 05 <0.05 0 05 0 05
" Copper mg/l l.0max - - <l.0 ! <l.0 <l.0 <l.0
_ Iron mg/l 0.3 max - - <0,3. i .<0.3 <0.3 <0.3
Lead _ mg/l 0.05 max - - <0.05 ....<0,05 <0.05 <0.05
Manganese mg/l 0.05 max .... <0.05 <0.05 <0.05 I <0.05
Mercury " mg/l 0.005 max - - <0.005 <0.005 <0.00,5I <0.005
Nickel mg/l O.05max - - <0.05 .......<0.05 <0.05 t <0.05
Selenium mg/l O.Ol max - - ..... .....; <O.Ol <O.Ol
Silver mg/l O.l max - - <0.05 <0.05 <O.l _ <O.l
Zinc mg/l 5.0 max - - <5.0 <5.0 <5.0 , <5.0
DissolvedGas @31°C _+ None Nqne None N/A N/A N/A N/A
Iodine....... mg/l.... 4.7 5.4 7.0 7.4 N/A N/A
Total ColiformBacteria #/lOOml 0 .... '0 0
Total Bacteria #/lOOml 0 .... 91 F,G 3F
Anaerobes + 0 - - - - 0 0
Yeast and Mold #/lOOml 0 .... 0 . 0
*None at threshold,no. of 3.
D. Chlorinetaste; odor #4.
E. Chlorinetaste; odor #17.
F. Pseudomonascepacia.
G. Pseudomonasalcaligenes,one Enterobacter.
-12-
SHUTTLETOXICOLOGY : : :
Wayland J. Rippstein: _
An atmospheric sampling program is conducted to characterize the outgassing
behavior of the •Orbiter .... !-
Since an unusually high level of toluene was detected in atmospheric sampies
, returned from the STS-2 mission, two preflight samples were collected for
STS-3. These were collected at the Kennedy Space Center (KSC) two weeks prior
to the STS-3 launch. Four atmospheric sampling cylinders were carried onboard
, STS-3 for inflight sampling purposes. The STS-3 crew collected samples just
after attaining orbit; just prior to deorbit; and on two occassions, equally
spaced, between the first and last sampling times.
Table I contains the analytical results of the two cabin atmospheric samples
taken just prior to the STS-3 launch. The main reason for taking these sam-
ples was to determine whether the toluene detected in the STS-2 mission was
still present at an elevated value. Toluene was detected in sample number 2,
but was present at a concentration of only 0.001 parts per million (ppm).
This level is of no consequence. Methane was present at 1.67 ppm and offered
no problem. The remaining 12 compounds were all well below the one part per
million level.
The only compoundspresentin concentrationsgreaterthan one part per million
were:
Compound Cabin Concentration SMAC*Value
i. carbon monoxide 2.28 ppm 25 ppm
2. methane 7.54 ppm 2700 ppm
3. bromotrifluoromethane (Halon 1301) 2.67 ppm i00 ppm
4. ethanol 1.21 ppm 50 ppm
*SMAC: spacecraft maximumallowable concentration.
The remaining36 compoundswere below the one part per million concentration
range. Evaluationof the 40 compounds using the toxicity group categories
method indicatedno hazard.
The resultsfrom the analysesof the two samplestaken just prior to the STS-3
mission provedthat the Orbitercabin had been cleanedof the toluenedetected
during the STS-3 mission. This may be accounted for by the new restrictions
imposedon the use of solventsin the cabin prior to the launch period.
The resultsfrom the analyses of the four samplestaken during the STS-3 mis-
sion indicated the presence of 40 compounds. Four of these compoundswere
presentin concentrationsabove 1 part per million.
This is the first time that carbonmonoxide reached the 2.28 ppm level. The
SMAC value for carbon monoxideis 25 ppm. STS-2 carbon monoxide stayed below
1 ppm while STS-2 carbon monoxideattaineda high value of 1.02 ppm.
25
Halon 1301was found in the last sampletakenduring the STS-3 mission at 2.67
ppm. It was learned from the debriefing records that one of the Orbiter's
hand held fire extinguishingdevices had been purposely discharged into an
avionicsbay area during the mission.
In conclusion,the STS-3 cabin atmospherepresentedno_toxichazard during the
mission. It is also noteworthyto point out that the crew did not indicate
any odor problemduring the STS-3 mission.
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TABLE1 _
STS-3 PREFLIGHTATMOSPHERICANALYSISa
COMPOUND SAMPLE1 SAMPLE2
• _ . .
Trichlorofluoromethane O.939 (0.167) I.709 (0.304)
, 1,1,2-Trichloro-1,2,2-Trifluorethane 0.284 (0.037) 1.020 (0..133)
Ethanal 0.189 (0,105)
Propanal _ _ ° ..... 0.014 (0.006)
2-Propanone: <0.002(<0.001) 0.007 (0.003)
-Butanal_ 0.026 (0.009)
2-Butanone 0.006 (0.002)
1,1,1-Trichloroethane 0.005 (0.001) 0.016 (0.003)
Dichloromethane; 0.031 (0.009) 0.059 (0.017) :
2 _Propanol _ 0.005 (0,002)
_Benzene ill <0.003(<0.001) <0.003(<0.001)
Toluene . . <0.004 (<0.001)
CarbonMonoxide <0.057(0.05) 1.067(1.631)
Methane 1.091 (1.668) 1.067 (1.631)
• aconcentrationsare in mg/m3, values in parenthesesare in p_
!
. _ • •
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RADIOLOGICALHEALTH
; Robert'G_iRichmondand B.L.Cash_
.. ...
Manned spaceflightresults in exposure of astronautsto a radiationenviron-
ment that is significantlymore complexthan that normallyassociatedwith the
radiologicalIhealth environment,for industrialworkers. , .
A record of all radiationexposure_receivedby the;astronautsismaintained as
part of the astronaut's medical record. The measured dose of radiation
encounteredby the space crew during each mission is added to the individual
crewman's medical record.
Permissibleradiationexposuresare providedfor each missionon a risk versus
gain basis by the JSC RadiationConstraintsPanel. These exposurelimits are
entered into the Flight Rules which are used to governthe mission. The basis
for radiationprotectionstandardsfor space flight is providedin guidanceby
the NationalAcademyof Sciences.
A constantwatch is maintainedto projectthe incidenceof potentiallyhazard-
ous radiationconditionswhich might occur during the mission. Incooperation
with the NationalOceanicand AtmosphericAdministrationand the Departmentof
Defense,constantevaluationof space environmentis conducted._
The results from the radiation instrumentation measurements aboard the
Columbia, STS-3, March 22-30, 1982, are presentedin-Table 1. This report
includes measurementsfrom the crew pocket dosimeters (CPD: low range, high
range, and high rate), the unshieldedthermoluminescentdosimeters(TLD). An
examination of the high energy-high atomic number (HZE) plastic detector
stackswas conductedalthoughthe data will not be presentedhere.
The dosimeterswere placed in pouches which were stowed on the spacecraft.
The Crew Activities Plan.(CAP) called for the dosimeters to be deployed
throughoutthe spacecraftat L+8 hours.
Prior to the mission, backgroundreadings for each instrumentwere taken and
the procedure developed.for extrapolatinga value for the backgroundat the
time of the postflightreadout. This procedurewas implementedas planned.
Data from the six low-rangepocket dosimetersare presentedin Table 1. These
data representthe corrected"flightdoses", i.e., the dose attributedto the
spaceflightalone. The backgroundcorrectionthat has been made consistsof:
(1) residualcharge impartedto the unit when zeroing it; (2) the leakage of
the charge with time; and (3) the recordingof the naturally-occurringradia-
tion background.
The measured doses from the CPD's are given in Table 1. The average flight
dose measured with the CPD's was 46.1 + 2.6 mRem. The CPD's worn by the
backup commanderand pilot were used to p_ovidebackgroundcorrectionsfor the
CPD's worn by the commanderand pilot. The averagesof the two control CPD
doses were used to provide a background subtractionfor the other flight
units.
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TABLE1. SUMMARYOF RADIATIONMEASUREMENTSFORSTS-3
TLD DOSE
(mRem) POCKET DOSIMETER
MEASURE}4ENT LOCATION TLD-200 TLD-700 DOSE (mRoentgen)
i
COMMANDER IN CLOTHING 41.5 47.1 NONE WORN
PILOT IN CLOTHING 45.0 45.9 NONE WORN
, POUCH 1 ON AIRLOCK, 48.7 49.0 57 + 3
ABOVE HATCH --
POUCH 2 ON OUTER WALL, 46.1 46.2 48 + 3
BEHIND & AFT DFI
POUCH 3 OUTER WALL, 40.7 44.4 53 + 3
ABOVE INGRESS/EGRESS
HATCH
POUCH 4 AFT, TOWARD 46.1 50.2 56 + 3
OF OBSERVATIONWINDOW
POUCH 5 ON CLOSEOUTPANEL, 50.4 44.4 55 + 3
ABOVE LOCKERL-IO
POUCH 6 ON CLOSEOUTPANEL, 45.2 46.0 58 + 3
ABOVE LOCKERR-11
i ...
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ENVIRONMENTALEFFECTSCFSHUTTLELAUNCHAND LANDING
AndrewPotter,Ph.D.
The environmentaleffectsof the exhaustcloud producedby the launch of STS-3
were monitored at the Kennedy Space Center (KSC), Florida. Acidic mist and
dust from the cloud were the main focus. The monitoringprogramcontainedthe
followlng elements:
o Exhaustcloud model,used to predictheightand directionof the cloud and
surfaceconcentrationsof dust and HCI.
w
o Monitoringstations,each includingpH paper, copper plates,HCI dosimeter
tubes, and a nucleoporefilter.
o Geomet units for gaseousHCI measurement.
o Air qualitymeasurements(03, SO2, etc.) prior to and during launch.
o Acousticnoise measurement.
o CIoud photography.
o Aircraftsamplingof cloud particles.
o Post-flightwater, sedimentand soil analysesof samplesnear the pad.
o Survey of benthic organisms on lagoons near the pad before and after
Iaunch.
o Survey of vegetationbefore and after launch.
Resultsand Discussion
Launch ExhaustCloud Dynamics
STS-3 was launched at Cape Canaveral,Florida, on March 22, 1982, at 10:00
a.m. EST. The weather conditions at launch were partly cloudy skies witho
surface_inds out of the southwest(240) at 3 knots. The surfacetemperature
was 26.1 C, with the relative humidity at 66%. The launch generateda cloud
of exhaust productswhich moved out to sea. The cloud was composedof alumi-
num oxide dust, liquid HCI aerosol, and gaseous HCI, plus a small amount of
dust swept up from the launch area. The launch cloud was observed and video
taped from the CIF Antenna Building, from which vantage point it appearedto
split into two parts at launch. One part travelednorth from the flame trench
and went out to sea in a northeasterlydirection. The second part went south
for about one kilometer and then traveled east out to sea. An additional
video tape recordingof the cloud was made from UCS6, near the VehicleAssem-
bly Building (VAB), and this recording indicateda similarcloud pattern. A
third recordingmade from the WildlifeLaboratoryarea, just south of Haulover
Canal, was of little value due to the poor visibilityat this site. Airborne
observersalso noted that the cloud split into two components,one at 1000 ft.
30
.... ; .. o _ •, . .. ..... . .
and the other at about 2000 ft. Bothkground'basedand airborne measurements--°
were made of the cloud. Ground-basedmeasurementswere limited, since the
cloud traveledover land only a short distancebefore going outto sea. Air,
borne measurementsfollowedthe cloud for about 35 miles.
SurfaceMeasurementsPlan
The measurementplan for STS-3 differedfrom STS-1 and STS-2, in that it was
reduced in scope, with most of the measurement sites determined fromcloud
model predictionsprior to the launch, rather than at fixed locations. Meas-
-" - urements were made of gaseous HCI, atmosphericparticulates,acidicmist and
dust deposition,biologicalimpacts,temperatureand acousticnoise. Particle
size distributions,wind velocityand temperaturewere measured in the exhaust
" plume at the north edge of the launch pad. Video recordingsas well as still
photographswere made of the launch and exhaust cloud from several•vantage
-- points. - -
Effect of the Launch Cloud on the Surface •_
,, , . . .......
Since the cloud traveled quickly out to sea, the surfacemeasurementsWere
confinedto the pad area and the regionbetweenthe pad and the beach.
.... The HCI dosimeterand HCI geomet data were not availableat the time of this o
report. However,the reactionof pH paper and copper plates at the pad sites
is indicativeof the HCI levels at these sites. The pH_paper showedbits of
dropletswith pH Values less than 1, and the copper plateswere blackened•from
exposureto HCI with pH values less than 1. _ •
. •. -_
i :
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